305 related articles for article (PubMed ID: 37359558)
1. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
[TBL] [Abstract][Full Text] [Related]
2. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
4. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
5. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
6. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
7. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
Qiao Y; Chen J; Wang X; Yan S; Tan J; Xia B; Chen Y; Lin K; Zou F; Liu B; He X; Zhang Y; Zhang X; Zhang H; Wu X; Lu L
Cancer Commun (Lond); 2023 Jul; 43(7):788-807. PubMed ID: 37282786
[TBL] [Abstract][Full Text] [Related]
9. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
11. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
12. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
13. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
15. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
18. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
[TBL] [Abstract][Full Text] [Related]
20. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
